Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionBank Of America Corp /de/
Latest Disclosed Ownership1,345,111 shares
Latest Disclosed Value $ 39,963,238
Bank Of America Corp /de/ ownership in TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Bank Of America Corp /de/ filed a 13F-HR form disclosing ownership of 1,345,111 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $39,963,248 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,850,355 shares of Travere Therapeutics, Inc.. This represents a change in shares of -27.31% during the quarter. The current value of the position is $60,799,017 USD.

Bank Of America Corp /de/ has a history of taking positions in derivatives of the underlying security (TVTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TVTX / Travere Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,345,111 -505,244 -27.31 39,963 -43.48 0.0007
2026-02-17 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,850,355 451,425 32.27 70,702 111.47 0.0051
2026-02-03 2025-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 1,398,930 -222,463 -13.72 33,434 39.33 0.0023
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,398,930 -222,463 33,434 0.0006
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,621,393 675,487 71.41 23,997 41.57 0.0018
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 945,906 -385,482 -28.95 16,951 -26.91 0.0014
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,331,388 -383,232 -22.35 23,193 -3.31 0.0019
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,714,620 -164,334 -8.75 23,988 55.31 0.0020
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,878,954 169,321 9.90 15,445 17.18 0.0014
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,709,633 88,166 5.44 13,181 -9.57 0.0012
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,621,467 406,241 33.43 14,577 34.17 0.0015
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,215,226 -134,277 -9.95 10,864 -47.59 0.0012
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,349,503 531,678 65.01 20,728 12.70 0.0022
2023-05-12 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 817,825 261,887 47.11 18,393 57.32 0.0019
2023-02-10 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 555,938 122,520 28.27 11,691 9.47 0.0013
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 433,418 -90,879 -17.33 10,680 -15.93 0.0013
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 524,297 -74,580 -12.45 12,704 -17.68 0.0014
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 598,877 87,507 17.11 15,433 -2.77 0.0015
2022-02-08 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 511,370 -444,060 -46.48 15,873 -31.49 0.0015
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 955,430 -717,055 -42.87 23,169 -5.05 0.0024
2021-09-13 2021-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 1,672,485 -763,586 -31.34 24,400 -59.89 0.0025
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,672,485 -763,586 24,400 0.0007
2021-05-14 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,436,071 37,438 1.56 60,828 -6.96 0.0068
2021-02-10 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,398,633 984,414 69.61 65,375 150.41 0.0084
2020-11-13 2020-09-30 13F RETROPHIN COM 761299106 1,414,219 6,011 0.43 26,107 -9.17 0.0036
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 1,408,208 -30,890 -2.15 28,743 36.90 0.0044
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 1,439,098 175,546 13.89 20,996 17.02 0.0038
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 1,263,552 107,193 9.27 17,942 33.88 0.0026
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 1,156,359 36,588 3.27 13,402 -40.42 0.0020
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 1,119,771 -365,492 -24.61 22,496 -33.07 0.0034
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 1,485,263 261,558 21.37 33,611 21.37 0.0052
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 1,223,705 652,895 114.38 27,693 68.87 0.0049
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 570,810 402,020 238.18 16,399 256.42 0.0026
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 168,790 25,911 18.13 4,601 44.05 0.0008
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 142,879 -18,705 -11.58 3,194 -6.20 0.0005
2018-02-14 2017-12-31 13F RETROPHIN COM 761299106 161,584 -4,462 -2.69 3,405 -17.59 0.0006
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 166,046 59,048 55.19 4,132 99.23 0.0007
2017-08-14 2017-06-30 13F RETROPHIN COM 761299106 106,998 9,578 9.83 2,074 15.35 0.0004
2017-05-15 2017-03-31 13F RETROPHIN COM 761299106 97,420 49,277 102.36 1,798 97.15 0.0004
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 48,143 22,382 86.88 912 58.33 0.0002
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 25,761 4,237 19.69 576 50.39 0.0001
2016-08-15 2016-06-30 13F RETROPHIN COM 761299106 21,524 11,597 116.82 383 183.70 0.0001
2016-05-13 2016-03-31 13F RETROPHIN COM 761299106 9,927 -4,844 -32.79 135 -52.63 0.0000
2016-02-16 2015-12-31 13F RETROPHIN COM 761299106 14,771 8,485 134.98 285 122.66 0.0001
2015-11-16 2015-09-30 13F RETROPHIN COM 761299106 6,286 -13,444 -68.14 128 -80.43 0.0000
2015-11-20 2015-06-30 13F/A-1 RETROPHIN COM 761299106 19,730 19,730 0.00 654 0.0002
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 19,730 654
2015-02-13 2014-12-31 13F RETROPHIN COM 761299106 0 -6,198 -100.00 0 -100.00
2014-11-14 2014-09-30 13F RETROPHIN COM 761299106 6,198 -3,502 -36.10 56 -50.88 0.0000
2014-08-14 2014-06-30 13F RETROPHIN COM 761299106 9,700 9,700 114 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-17 2025-12-31 13F TRAVERE THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-03 2025-09-30 13F/A TRAVERE THERAPEUTICS COM Call 80,000 0.00 1,912 61.49 n/a n/a n/a
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM Call 80,000 1,912 n/a n/a n/a
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM Call 80,000 -33.33 1,184 -44.93 n/a n/a n/a
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM Call 120,000 0.00 2,150 2.87 n/a n/a n/a
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM Call 120,000 0.00 2,090 24.55 n/a n/a n/a
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM Call 120,000 1,679 n/a n/a n/a
2018-11-14 2018-09-30 13F RETROPHIN OPTIONS Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F RETROPHIN OPTIONS Call 331,600 0.00 9,039 21.90 n/a n/a n/a
2018-05-15 2018-03-31 13F RETROPHIN OPTIONS Call 331,600 0.00 7,415 6.13 n/a n/a n/a
2018-02-14 2017-12-31 13F RETROPHIN OPTIONS Call 331,600 6,987 n/a n/a n/a
2016-02-16 2015-12-31 13F RETROPHIN OPTIONS Call 0 0 n/a n/a n/a
2015-11-16 2015-09-30 13F RETROPHIN OPTIONS Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-11-20 2015-06-30 13F/A RETROPHIN OPTIONS Call 8,100 269 n/a n/a n/a
2015-08-14 2015-06-30 13F RETROPHIN OPTIONS Call 8,100 269 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.